Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Porfimer sodium
Drug ID BADD_D01803
Description The purified component of hematoporphyrin derivative, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (hematoporphyrin photoradiation); to treat malignant lesions with visible light and experimentally as an antiviral agent. It is the first drug to be approved in the use of photodynamic therapy in the United States.
Indications and Usage Indicated in the treatment of esophageal cancer.
Marketing Status Prescription
ATC Code L01XD01
DrugBank ID DB00707
KEGG ID D03327
MeSH ID D017323
PubChem ID 135577896
TTD Drug ID D02JDL
NDC Product Code 76128-155
Synonyms Dihematoporphyrin Ether | Ether, Dihematoporphyrin | Dihematoporphyrin Ester | Porfimer | DHP Ether | Porfimer Sodium | Photofrin | Photofrin II
Chemical Information
Molecular Formula C68H74N8O11
CAS Registry Number 87806-31-3
SMILES CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C(C)O)C)C(=C4C)C(C)OC(C)C6=C(C7=CC 8=C(C(=C(N8)C=C9C(=C(C(=N9)C=C1C(=C(C(=N1)C=C6N7)C)CCC(=O)O)CCC(=O)O)C)C)C(C)O)C )C(=C3CCC(=O)O)C)CCC(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypotension24.06.03.0020.001865%
Ileus07.13.01.001--
Immune system disorder10.02.01.001--Not Available
Increased tendency to bruise24.07.06.012; 23.06.01.009; 01.01.03.005--Not Available
Infection11.01.08.0020.000208%Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.001--Not Available
Insomnia19.02.01.002; 17.15.03.0020.000799%
Jaundice09.01.01.004; 01.06.04.004; 23.03.03.030--Not Available
Joint contracture15.01.08.001--Not Available
Keloid scar23.01.03.002--Not Available
Laryngotracheal oedema23.04.01.011; 22.04.02.005; 10.01.05.011--Not Available
Lentigo23.05.01.011--Not Available
Lethargy08.01.01.008; 19.04.04.004; 17.02.04.003--
Leukocytosis01.02.01.002--
Liver abscess11.01.18.001; 09.01.11.0010.000533%Not Available
Malaise08.01.01.003--
Mediastinitis22.09.03.002; 11.01.08.0270.000533%
Melaena24.07.02.013; 07.12.02.004--Not Available
Melanocytic naevus23.10.01.007; 16.26.01.007--Not Available
Menopausal symptoms21.02.02.002--Not Available
Milia23.02.03.011--Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Nasal congestion22.04.04.001--
Nausea07.01.07.0010.001066%
Neoplasm16.16.02.001--Not Available
Neoplasm malignant16.16.01.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Neuralgia17.02.07.0050.000533%
Neuropathy peripheral17.09.03.0030.000799%Not Available
Night sweats23.02.03.006; 08.01.03.031--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 9 Pages